Antiemetic Prophylaxis for Postdischarge Nausea and Vomiting After Hip Arthroscopy

• Status: Completed
• Trial end date: 2010-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is a randomized placebo controlled trial to determine whether repeated postoperative prophylactic ondansetron ("Zofran") administration will prevent postoperative and/or postdischarge nausea and vomiting in patients undergoing ambulatory hip arthroscopy. Ondansetron will be administered in the intra- and post-operative period. These individuals will be followed on postoperative days 1, 2, and 3. It is hypothesized that the incidence of postdischarge nausea and vomiting (PDNV) will be significantly decreased by postoperative prophylactic administration of multiple doses of ondansetron (Zofran).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital for Special Surgery, New York
• Treatments: Antiemetics; Ondansetron

Criteria

Inclusion Criteria:

• All patients of Dr. Coleman or Dr. Kelly ages 18 to 65 undergoing arthroscopic hip surgery

• Planned use of neuraxial anesthesia

• Ability to follow study protocol

• Willing to complete daily diary and be interviewed daily for three days after discharge

Exclusion Criteria:

• Patients younger than 18 years old and older than 65

• Patients unable to undergo a spinal or epidural anesthetic

• Having nausea or vomiting within 24 hours of the surgery

• Receiving drugs with anti-emetic properties within 24 hours of the surgery (e.g Zofran, Compazine, Phenergan, Reglan)

• Chronic opioid use (defined as daily or almost daily use of opioids for >3 months)

• Hypersensitivity and/or allergy to ondansetron

• Intraoperative use of any volatile anesthetic

• Contraindication to a short course of NSAIDs (renal failure, intolerance)

• Allergy or intolerance to Vicodin